Clinical trial
Spironolactone in the Treatment of Heart Failure- a Double-blind, Randomized, Placebo-controlled, Parallel Group Interventional Phase III Study to Determine Efficacy and Safety of Spironolactone on the Composite Endpoint of Recurrent Heart Failure Hospitalizations and Cardiovascular Death in Patients with Heart Failure with Mid-range or Preserved Ejection Fraction
NCT04727073 is registered in ClinicalTrials.gov with Charite University, Berlin, Germany as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Spironolactone in the Treatment of Heart Failure- a Double-blind, Randomized, Placebo-controlled, Parallel Group Interventional Phase III Study to Determine Efficacy and Safety of Spironolactone on the Composite Endpoint of Recurrent Heart Failure Hospitalizations and Cardiovascular Death in Patients with Heart Failure with Mid-range or Preserved Ejection Fraction
- Lead sponsor
- Charite University, Berlin, Germany
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- November 1, 2018
- Completion date
- October 1, 2024
- Enrollment
- 743 (actual)
- Sites
- 69
Conditions
As the registry lists them; a condition with its own page is linked.
heart failure with mid-range ejection fraction, heart failure with preserved ejection fraction